The Healthspan Pivot
Evaluating the 2024 clinical shift from simple lifespan extension to the proactive preservation of functional quality.
Primary Objective
Compressed Morbidity
Targeting the 'biological cliff' to occur in the final 2% of the lifespan, maintaining peak function longer.
Key Mechanism
STING Inhibition
Preventing the 'cytokine storm' triggered by cellular DNA leakage as discovered in the Leiden studies.
Statistical Power
p < 0.001
High statistical significance achieved in recent longitudinal meta-analyses across global cohorts.
Functional Capacity Projections: 1950 vs 2024 Models
Source: Bio-Longevity FrameworkThe CGAS Pathway Significance
Research from the Leiden Longevity Study identifies the cyclic GMP-AMP synthase (CGAS) gene as the absolute "Master Sensor" of biological decay.
The Discovery: DNA Leakage
"As cells age, nuclear and mitochondrial DNA leak into the cytoplasm. The CGAS sensor incorrectly identifies this as a viral invasion, triggering a chronic inflammatory fire (The STING Pathway)."
Centenarian bloodlines show a unique, inheritable ability to downregulate this inflammatory cascade, preserving tissue integrity and organ function long after traditional biological clocks expire.
Systemic Cytokine Load
Comparison of inflammaging markers across cohorts
Proteostasis & Mitochondrial Clean-up
The Max Planck Institute for the Biology of Ageing has demonstrated that survival rates are directly proportional to the efficiency of cellular recycling.
- 1 Proteostasis: The ability to clear misfolded proteins before they clump.
- 2 Mitophagy: The destruction and recycling of damaged, energy-leaking mitochondria.
Cologne in vivo Experiments: Mitophagy vs Age
Plotting recycling efficiency against biological age units.
The 2024 Validity Matrix
An exhaustive comparison of recent longevity studies based on Statistical Validity (Power/p-value) and Global Peer Consensus.
High Validity Tier
Leiden (CGAS) and Max Planck (Proteostasis) exhibit the strongest replication scores of 2024. Both have shown high statistical power in independent research networks across multiple mammalian models, cementing their status as primary therapeutic targets.
Emerging / Debate Tier
Senolytic trials and Epigenetic Reprogramming (OSK factors) show extremely high peer interest, but currently fluctuate in statistical validity. Issues include study heterogeneity in human trials and ongoing debates regarding tumorigenic risks in reprogramming.